Dapawalf 10 mg Tablet

Dapawalf 10 mg Tablet contains Dapagliflozin 10 mg. Prescription required.

Type 2 diabetes mellitus (to improve glycaemic control along with diet and exercise); may be used in patients with cardiovascular risk and/or chronic kidney disease or heart failure as per clinician advice

Dapagliflozin is an SGLT2 inhibitor that reduces reabsorption of glucose in the kidneys. It increases urinary glucose excretion, thereby lowering blood sugar and causing mild osmotic diuresis.

Oral tablet. Typically taken once daily, at the same time each day, with or without food. Dose and duration as prescribed; maintain hydration and follow diet/exercise advice.

Genital fungal infection, urinary tract infection, increased urination, thirst, dizziness, low blood pressure, nausea, constipation

Risk of dehydration and low blood pressure (especially in elderly, on diuretics); genital mycotic infections and UTIs; rare but serious ketoacidosis (seek urgent care for nausea/vomiting, abdominal pain, rapid breathing); monitor kidney function—use with caution in renal impairment and avoid if severe renal dysfunction as advised by doctor; risk of hypoglycaemia when combined with insulin/sulfonylureas; stop temporarily during major surgery/acute serious illness or prolonged fasting as advised; not for type 1 diabetes.

Insulin and sulfonylureas (increased hypoglycaemia risk), diuretics (increased dehydration/hypotension risk), antihypertensives (additive BP lowering), lithium (levels may change with diuresis), other SGLT2 inhibitors (duplication)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Forxiga 10 mg Tablet, Dapaworth 10 mg Tablet, Dapanorm 10 mg Tablet, Dapaglyn 10 mg Tablet, Dapatab 10 mg Tablet